CSTL - Castle Biosciences Annual Revenue Growth (Last Twelve Months)

Castle Biosciences relies on physician adoption of DecisionDx tests and insurance reimbursements. The engagement of oncology experts ensures diagnostic accuracy, which serves as a key growth driver. Price stability is dictated by US insurance tariffs. The LTM annual change in sales volume on the GURU.Markets chart clearly demonstrates this trend, while the 9.70 metric confirms the current level of revenue dynamics.
Summary analytical data breakdowns for Castle Biosciences Inc (CSTL)

Long-term risk control requires an analysis of revenue stability via smoothed growth rates over a rolling year, which reflects year-over-year sales growth (TTM). For Castle Biosciences (CSTL), this trend confirms the effective scaling of diagnostic tests, where the high margins of innovation combined with decreasing unit costs transform operating leverage into actual growth in market capitalization and net income.